论文部分内容阅读
目的:系统地研究围介入术期在高危非ST段抬高型急性冠脉综合征患者中应用替罗非班的实际价值。方法:选取韶关市粤北人民医院收治的100例高危非ST段抬高型急性冠脉综合征患者分组研究,结合临床随机表法将其平均分为观察组与对照组,100例患者在手术前均行氯吡格雷、阿司匹林常规抗凝治疗,然后对其行经皮冠状动脉介入治疗和冠状动脉造影术治疗,在此基础上,观察组加用替罗非班,对比两组治疗有效率、心功能指标和心血管事件的发生率。结果:两组患者心功能指标对比,差异具有统计学意义(P<0.05);观察组的治疗有效率是94.0%,心血管事件的发生率6.0%,对照组的治疗有效率是80.0%,心血管事件的发生率26.0%,差异具有统计学意义(P<0.05)。结论:围介入术期在高危非ST段抬高型急性冠脉综合征患者中应用替罗非班能够有效地改善患者的心功能,提高治疗有效率,降低心血管事件的发生率。
OBJECTIVE: To systematically investigate the practical value of perioperative intervention for the use of tirofiban in high-risk non-ST segment elevation acute coronary syndrome patients. Methods: A total of 100 patients with high-risk non-ST-segment elevation acute coronary syndrome admitted to Yuebei People’s Hospital of Shaoguan City were divided into observation group and control group according to randomized clinical trial. 100 patients underwent surgery Before the implementation of clopidogrel, aspirin conventional anticoagulant therapy, and then its percutaneous coronary intervention and coronary angiography, on this basis, the observation group plus tirofiban, compared two groups of treatment efficiency, Cardiac function and incidence of cardiovascular events. Results: There were significant differences in cardiac function between the two groups (P <0.05). The effective rate of treatment in the observation group was 94.0%, the incidence of cardiovascular events was 6.0% and the control group was 80.0% The incidence of cardiovascular events was 26.0%, the difference was statistically significant (P <0.05). Conclusion: Perioperative intervention with tirofiban in patients with high-risk non-ST-segment elevation acute coronary syndrome can effectively improve the cardiac function, improve the treatment efficiency and reduce the incidence of cardiovascular events.